CEO and co-founder of BoostSuite
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Co-Founder and CEO, Wetpaint
Managing director, the Foundry Group
Following a highly successful presentation during the recent BIO International Convention, Campbell Alliance is scheduled to present the results of its fourth annual “dealmakers’ intentions survey,” the only forward-looking measure of deal-making activity in the pharmaceutical and biotech industries. In addition to Campbell’s prospective view of the partnering and licensing landscape, Campbell Vice President Jeff Liepman will moderate a deals discussion with executives from Cadence Pharmaceuticals, Halozyme Therapeutics, Ambit Biosciences, Receptos, and Tracon Pharmaceuticals. More information and online registration is here.